Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Longer overall survival and similar safety profile were the endpoints in this NEJM piece, comparing those who received osimertinib with those who received a comparator EGFR-TKI.
Internal Medicine March 16th 2020
Can transfusion independence for multiple weeks be possible in patients with myelodysplastic syndromes? Read on to discover promising information you can share with your patients about reducing the severity of their anemia.
Hematology March 16th 2020
NEJM explores the question: Are we, in fact, what we eat? Can the periodic flipping of a “metabolic switch” truly help patients?
Allergy & Immunology March 16th 2020